Ireland's pharmaceutical industry shipped billions' worth of goods to the U.S., but face threats from Trump 2.0.
A groundbreaking study shows how Zepbound, a popular weight loss medication, could become a key treatment for heart failure ...
It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...
People taking weight-loss drugs say they are losing their sight. Science is trying to figure out why
Several patients using brand-name drugs like Ozempic, Wegovy, Mounjaro, and Zepbound experienced problems ... from Mass Eye and Ear found that some people prescribed semaglutide have a higher ...
Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound ... improve the lives of people living with obesity,” Coleman ...
The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide ... In a key secondary endpoint, 31.6% of people taking tirzepatide achieved at least 25% ...
The study included people taking different types drugs in this category—semaglutide (Wegovy and Ozempic), and tirzepatide (Mounjaro and Zepbound). While tirzepatide targets two hormones—GLP-1 ...
Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for ... approved treatment for the roughly 20 million people with the disorder.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback